Chemokine (C-C motif) Ligand 2 Is Regulated Through the EGFR/Src Pathway in HER2-positive Breast Cancer Cells
- Authors
- You, D.[You, D.]; Kim, H.[Kim, H.]; Jeong, Y.[Jeong, Y.]; Yoon, S.Y.[Yoon, S.Y.]; Lo, E.[Lo, E.]; Lee, J.E.[Lee, J.E.]; Kim, S.[Kim, S.]
- Issue Date
- 1-Mar-2023
- Publisher
- International Institute of Anticancer Research
- Keywords
- C-C chemokine receptor type 2; Chemokine (C-C motif) ligand 2; epidermal growth factor receptor; human epidermal growth factor receptor 2; Src
- Citation
- Anticancer Research, v.43, no.3, pp.1079 - 1089
- Indexed
- SCIE
SCOPUS
- Journal Title
- Anticancer Research
- Volume
- 43
- Number
- 3
- Start Page
- 1079
- End Page
- 1089
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/104419
- DOI
- 10.21873/anticanres.16253
- ISSN
- 0250-7005
- Abstract
- Background/Aim: Chemokine (C-C motif) ligand 2 (CCL2) influences growth and metastasis and is associated with poor prognosis in various cancers. However, the regulatory mechanism of CCL2 induction by human epidermal growth factor receptor 2 (HER2) is not fully understood in breast cancer. Thus, we investigated how CCL2 expression is regulated in HER2-positive (HER2+) breast cancer. Materials and Methods: A human cytokine array was performed to investigate the differential expression of cytokines by HER2 overexpression. Quantitative reverse transcription PCR, enzyme-linked immunosorbent assay and western blot were performed to detect the levels of mRNA and protein expression. Cell cycle and proliferation were analyzed by flow cytometry. Cell invasion was analyzed by Boyden chamber assay. Results: Our results showed that HER2 overexpression augmented CCL2 expression. Epidermal growth factor receptor (EGFR) and Src activities were increased in the HER2-overexpressed breast cancer cells. Interestingly, HER2-induced CCL2 expression could not be down-regulated by trastuzumab, while neratinib or saracatinib led to a decrease in the expression of CCL2 in HER2+ breast cancer cells. Conclusion: CCL2 expression is regulated through the EGFR/Src-dependent signaling in HER2+ breast cancer. © 2023 International Institute of Anticancer Research. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/104419)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.